Literature DB >> 34011522

Th17 Cells Contribute to the Pathology of Autoimmune Hypophysitis.

Paulina Chalan1, Nithya Thomas1, Patrizio Caturegli2.   

Abstract

Autoimmune hypophysitis is classified as primary if its origin is idiopathic and secondary if it develops as a consequence of treatment with immune checkpoint inhibitors. Expanding use of immunotherapy has been paralleled by the increasing hypophysitis prevalence. However, understanding of the immune responses driving the disease remains limited. Using a mouse model of primary hypophysitis, we have identified CD4+ T lymphocytes to be the main pituitary-infiltrating immune cell population. Functional analysis showed that they display a Th17 and Th1/Th17 phenotype. To examine involvement of proinflammatory Th1, Th17, and Th1/17 subsets in hypophysitis, we have isolated RNA from the formalin-fixed paraffin-embedded pituitary specimens from 16 hypophysitis patients (three of whom had hypophysitis secondary to immune checkpoint inhibitors), 10 patients with adenoma, and 23 normal pituitaries obtained at autopsy. Transcript levels of IFN-γ, IL-17A, IL-4, IL-10, TGF-β, CD4, CD8α, and class II MHC transactivator were analyzed by the reverse transcription-quantitative PCR (RT-qPCR). Pituitary glands of patients with hypophysitis showed significantly higher IL-17A, CD4, and class II MHC transactivator mRNA levels compared with adenoma and normal pituitaries. All three secondary hypophysitis patients showed detectable IL-17A levels, but other cytokines were not detected in their pituitaries. Levels of IFN-γ, IL-4, IL-10, and TGF-β did not differ between the groups. TGF-β transcript was found in significantly fewer hypophysitis pituitaries (2 out of 16) compared with adenoma (7 out of 10) and normal pituitaries (11 out of 23). Presence of TGF-β in two hypophysitis patients was associated with significantly lower IL-17A mRNA levels compared with hypophysitis patients with no detectable TGF-β (p = 0.03).
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34011522      PMCID: PMC9245460          DOI: 10.4049/jimmunol.2001073

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  41 in total

Review 1.  Reasons for rarity of Th17 cells in inflammatory sites of human disorders.

Authors:  Francesco Annunziato; Veronica Santarlasci; Laura Maggi; Lorenzo Cosmi; Francesco Liotta; Sergio Romagnani
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

2.  Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.

Authors:  Salahaldin A Tahir; Jianjun Gao; Yuji Miura; Jorge Blando; Rebecca S S Tidwell; Hao Zhao; Sumit K Subudhi; Hussein Tawbi; Emily Keung; Jennifer Wargo; James P Allison; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

3.  Preparation of mouse pituitary immunogen for the induction of experimental autoimmune hypophysitis.

Authors:  Shey-Cherng Tzou; Melissa A Landek-Salgado; Hiroaki Kimura; Patrizio Caturegli
Journal:  J Vis Exp       Date:  2010-12-17       Impact factor: 1.355

4.  Transforming growth factor-beta induces development of the T(H)17 lineage.

Authors:  Paul R Mangan; Laurie E Harrington; Darrell B O'Quinn; Whitney S Helms; Daniel C Bullard; Charles O Elson; Robin D Hatton; Sharon M Wahl; Trenton R Schoeb; Casey T Weaver
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

5.  The immunoregulatory role of CD4⁺ FoxP3⁺ CD25⁻ regulatory T cells in lungs of mice infected with Bordetella pertussis.

Authors:  Michelle M Coleman; Conor M Finlay; Barry Moran; Joseph Keane; Pádraic J Dunne; Kingston H G Mills
Journal:  FEMS Immunol Med Microbiol       Date:  2012-01-18

Review 6.  Autoimmune hypophysitis.

Authors:  Patrizio Caturegli; Craig Newschaffer; Alessandro Olivi; Martin G Pomper; Peter C Burger; Noel R Rose
Journal:  Endocr Rev       Date:  2005-01-05       Impact factor: 19.871

7.  A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.

Authors:  Jeroen de Filette; Corina Emilia Andreescu; Filip Cools; Bert Bravenboer; Brigitte Velkeniers
Journal:  Horm Metab Res       Date:  2019-03-12       Impact factor: 2.936

8.  T regulatory cells distinguish two types of primary hypophysitis.

Authors:  S Mirocha; R B Elagin; S Salamat; J C Jaume
Journal:  Clin Exp Immunol       Date:  2008-12-05       Impact factor: 4.330

9.  Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells.

Authors:  Natalia Martin-Orozco; Yeonseok Chung; Seon Hee Chang; Yi-Hong Wang; Chen Dong
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

10.  The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.

Authors:  Nicolas Manel; Derya Unutmaz; Dan R Littman
Journal:  Nat Immunol       Date:  2008-05-04       Impact factor: 25.606

View more
  3 in total

Review 1.  Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle.

Authors:  Agnese Barnabei; Andrea Corsello; Rosa Maria Paragliola; Giovanni Maria Iannantuono; Luca Falzone; Salvatore Maria Corsello; Francesco Torino
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

Review 2.  Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Authors:  Agnese Barnabei; Lidia Strigari; Andrea Corsello; Rosa Maria Paragliola; Luca Falzone; Roberto Salvatori; Salvatore Maria Corsello; Francesco Torino
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

Review 3.  Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease.

Authors:  Fabienne Langlois; Elena V Varlamov; Maria Fleseriu
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.